Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Bill Steinman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Shruti J. Shah
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
In 2020, the DOJ and SEC brought FCPA enforcement actions against 12 companies and imposed financial penalties totaling a record $6.4 billion. For a comparison, in 2019, 14 companies paid a (then) record $2.9 billion to resolve FCPA cases.… Continue Reading
I’m not defending what Novartis did or trying to find an excuse for the company. It violated the FCPA, and (along with a former subsidiary) paid nearly $347 million in penalties and disgorgement to resolve the offenses.… Continue Reading
During the research for our new book about compliance and ethics, we saw how organizations across the world continue to be damaged and brought down by systemic non-compliance or the misdeeds of a few.… Continue Reading
Pharmaceuticals companies continue to fall foul of the FCPA and other anti-bribery laws, with a number of 2016 cases suggesting a vulnerability around marketing practices especially in the Asia-Pacific region. Why does a sector that is way ahead of the compliance game in so many ways keep getting caught out by anti-bribery laws?… Continue Reading
Last month Forest Labs paid $38 million to settle allegations it paid doctors speaker fees for sometimes phony events so they would prescribe its drugs. It was the latest in a string of “speaker fee” cases.… Continue Reading
The Securities and Exchange Commission Tuesday charged U.K.-based pharma AstraZeneca PLC with violating the books and records and internal controls provisions of the Foreign Corrupt Practices Act when wholly-owned subsidiaries in China and Russia made illegal payments to boost drug sales.… Continue Reading
Pharma AstraZeneca LP agreed to pay $7.9 million to settle allegations that it violated the False Claims Act by paying kickbacks to sell its drugs, the DOJ said.
AstraZeneca markets and sells pharmaceutical products in the United States, including a drug sold under the trade name Nexium.… Continue Reading
Image courtesy of GlaxoSmithKlineA police investigation in China has found that drugmaker GlaxoSmithKline’s alleged bribery of doctors ‘was coordinated by the British company and was not the work of individual employees,’ according to a report Tuesday by Reuters.… Continue Reading
Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.
“It is rumored that police in plain clothes are patrolling in hospitals; drug sales representatives will be fined 500 yuan ($81) and regional sales managers 1000 yuan ($162) once being caught in hospitals,” an unidentified sales representative told the paper.… Continue Reading
China state media reported Saturday that French drugmaker Sanofi SA is under investigation for allegedly bribing doctors to increase sales.
The Xinhua news agency said more than 500 Chinese doctors are suspected of accepting bribes from the company.… Continue Reading
Recent turbulence in China for drug makers follows big problems for members of the industry in the United States, where they’ve paid billions in criminal fines and civil penalties.
Here’s a quick rundown of their U.S.… Continue Reading
The headlines from Tuesday’s ethiXbase Monitor, a daily email of global corruption and compliance news, tell the story.
Here are the first four items:
… Continue ReadingChina: Glaxo Executive Says Changes in China to Cut Drug Prices
Published on Jul 24, 2013 03:00 am
GlaxoSmithKline Plc (GSK)’s head of emerging markets said after meeting with government officials in Beijing some employees may have broken China’s laws and pledged corporate changes that will deliver cheaper medicines.
